Skye Bioscience Inc —— 资产负债表 (NASDAQ:SKYE) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 2.67 M9.86 M9.11 M11.94 M72.76 M28.31 M 负债总额 2.22 M3.99 M12.12 M14.07 M4.61 M8.29 M 权益总额 450.79 K5.86 M-3.01 M-2.13 M68.15 M20.02 M 负债及股东权益总额 2.67 M9.86 M9.11 M11.94 M72.76 M28.31 M 总债务 1.5 M1.97 M78.7 K-21.79 K-5.98 M— 净债务 -971.61 K-7.01 M-1.19 M-1.28 M-74.39 M—

新闻

Cantor Fitzgerald重申Skye Bioscience股票评级为中性

Cantor Fitzgerald reiterates Skye Bioscience stock rating at Neutral

Citizens重申Skye Bioscience股票评级,看好减肥数据表现

Citizens reiterates Skye Bioscience stock rating on weight loss data

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye 2025年第四季度业绩:尼马西单抗联合疗法显示额外减重3%

Skye Q4 2025 slides: nimacimab combination shows 3% added weight loss

H.C. Wainwright维持Skye Bioscience股票20美元买入评级

H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20

Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year - Skye Bioscience (NASDAQ:SKYE)

Nimacimab-司美格鲁肽组合疗法在52周时实现22.3%的体重减轻

Nimacimab-semaglutide combo shows 22.3% weight loss at 52 weeks